Pfizer Inc (Pfizer) is a biopharmaceutical company that operates in approximately 200 countries and territories. Its product portfolio includes a wide range of products and services across various therapeutic areas such as cardiovascular, metabolic diseases, migraine treatments, vaccines, inflammation, oncology, immunology, rare diseases, and hospital medicines. The company collaborates with alliance partners and distributors to ensure the availability of its products across various markets. Some of its major brands include Eliquis, Nurtec ODT/Vydura, Zavzpret, Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, Paxlovid, Xeljanz, Enbrel, Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, Vyndaqel family, Genotropin, BeneFIX, Xyntha, and Somavert, among others.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Pfizer is focused on delivering a pipeline of highly differentiated medicines and vaccines, advancing capabilities for long-term R&D leadership, and developing new models for partnerships to deliver innovation to patients. The company's R&D primarily focuses on oncology, internal medicine (including cardiovascular and migraine), vaccines, and inflammation and immunology. It also develops new drugs through collaboration, alliance, and license agreements with universities, biotechnology companies, other firms, and through acquisitions and investments. Pfizer’s R&D activities are managed by the consolidated Oncology R&D (ORD) organization, which spans discovery to late-phase clinical development for oncology, and Pfizer Research and Development (PRD), which manages the remaining therapeutic areas and certain platform organizations. The company operates R&D facilities in the US, the UK, India, and Belgium. In FY2025, the company spent US$10,437 million on its R&D activities, which as a percentage of revenue stood at 16.7%. As of February 2026, the company had 102 pipeline products, including 38 in phase 1, 30 in phase 2, 32 in phase 3, and two in registration. It owns numerous US and foreign patents covering pharmaceutical and other products and their uses, product manufacturing processes, pharmaceutical formulations, and intermediate chemical compounds used in the manufacture of its products. Some of its pipeline products in phase III include LITFULOTM (ritlecitinib) to treat vitiligo, dazukibart (PF06823859) to treat dermatomyositis and polymyositis, hympavzitm (marstacimab) to treat hemophilia in pediatric, osivelotor (PF07940367) to treat sickle cellibuzatrelvir (PF07817883) to treat covid-19 infection, nurtec (rimegepant) to treat menstrually-related migraine, ibrance (palbociclib) to treat er+/her2+ metastatic breast cancer, sigvotatug vedotin (PF08046047) to treat 2l+ metastatic non-small cell lung cancer, disitamab vedotin (PF08046051) to treat 1l her2 (=ihc1+) metastatic urothelial cancer (DV001), mevrometostat (PF06821497) + enzalutamide to treat 1/2l metastatic castration resistant prostate cancer postabiraterone (mevpro-1), PF06425090 to treat primary clostridioides difficile, PF07307405 to treat lyme disease, and giroctocogene fitelparvovec (PF07055480) to treat hemophilia A, among others.